| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 19.671 | 20.839 | 20.568 | 23.351 | 26.659 | 23.008 | 27.683 | 34.013 | 40.174 | 67.377 |
| Total Income - EUR | 19.671 | 20.839 | 20.568 | 23.351 | 26.659 | 23.008 | 27.683 | 34.013 | 40.174 | 67.377 |
| Total Expenses - EUR | 21.079 | 14.365 | 16.645 | 17.148 | 16.666 | 19.720 | 21.925 | 26.140 | 32.497 | 41.504 |
| Gross Profit/Loss - EUR | -1.409 | 6.474 | 3.922 | 6.204 | 9.993 | 3.288 | 5.758 | 7.873 | 7.678 | 25.874 |
| Net Profit/Loss - EUR | -1.998 | 6.057 | 3.717 | 5.970 | 9.726 | 3.068 | 5.481 | 7.540 | 7.284 | 23.475 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Dr. Slusar Daomed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 393 | 389 | 383 | 376 | 368 | 361 | 353 | 354 | 353 | 60.417 |
| Current Assets | 4.780 | 6.727 | 4.182 | 9.983 | 13.616 | 16.941 | 22.094 | 19.550 | 26.643 | 10.453 |
| Inventories | 468 | 940 | 993 | 2.095 | 1.203 | 1.180 | 1.154 | 1.157 | 0 | 0 |
| Receivables | 1.012 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 3.300 | 5.787 | 3.189 | 7.889 | 12.413 | 15.762 | 20.941 | 18.393 | 26.643 | 10.453 |
| Shareholders Funds | 4.354 | 6.135 | 3.838 | 9.738 | 13.375 | 16.189 | 21.311 | 18.779 | 26.005 | 49.335 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 820 | 981 | 727 | 621 | 609 | 1.113 | 1.136 | 1.126 | 991 | 21.535 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8621 - 8621" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Dr. Slusar Daomed Srl